ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Systematic Pan-Cancer Analysis of KLRB1 with Prognostic Value and Immunological Activity across Human Tumors

Cheng, Xin; Cao, Yucheng; Wang, Xiaowei; Cheng, Lin; Liu, Yaqiong; Lei, Jun; Peng, Weijun*; Shi, Dazun*广州中医药大学
Journal of Immunology Research2022-1-6DOI: 10.1155/2022/5254911
16被引2阅读
引用收藏
分享

摘要

Introduction. KLRB1 is a gene encoding CD161 expressed in NK cells and some T cell subsets. At present, KLRB1 is believed to affect tumorigenesis and development by regulating the cytotoxicity of NK cells in several cancers. However, there is a lack of systematic reviews of KLRB1 in a variety of malignancies. Objectives. Hence, our research is aimed at providing a relatively comprehensive understanding of the role of KLRB1 in different types of cancer, paving the way for further research on the molecular mechanism and immunotherapy potential of KLRB1. Methods. In this study, we used relevant public databases, including TCGA (The Cancer Genome Atlas), GEO (Gene Expression Omnibus), CCLE (Cancer Cell Line Encyclopedia), GTEx (Genotype Tissue-Expression), and HPA (Human Protein Atlas), to perform a pan-cancer analysis of KLRB1 across 33 types of cancer. We explored the potential molecular mechanism of KLRB1 in clinical prognosis and tumor immunity from the aspects of gene expression, survival status, clinical phenotype, immune infiltration, immunotherapy response, and chemotherapeutic drug sensitivity. Results. KLRB1 was downregulated in 13 cancers while upregulated in kidney cancer. Patients with high expression of KLRB1 have a better prognosis in most types of cancer. Moreover, the KLRB1 expression level is related to TMB and MSI and related to various immune signatures of tumor. The expression of KLRB1 can affect tumor immune cell infiltration. KLRB1 expression level can also affect the sensitivity of chemotherapy drugs. Conclusions. KLRB1 may be a prognostic and immunological biomarker across tumors. At the same time, KLRB1 expression can reflect the sensitivity of cancer patients to chemotherapy drugs. KLRB1 may become a new target for immunotherapy.

学科与关键词

关键词
HUMAN NKR-P1AT-CELLSCD161IMMUNOTHERAPYRECEPTORACTIVATIONEXPRESSIONLANDSCAPEMOLECULELIGAND
相关
加载中…
  • A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint
    Zhou, Xiaohan; Du, Jun; Liu, Chengdong; Zeng, Hanyi; Chen, Yuting; Liu, Li*; Wu, Dehua*Frontiers in Immunology, 2021, 12: 688215.被引 34
  • A pan-cancer and single-cell sequencing analysis of CD161, a promising onco-immunological biomarker in tumor microenvironment and immunotherapy
    Li, He; Zhou, Ke; Wang, Kaiyue; Cao, Hui; Wu, Wantao; Wang, Zeyu; Dai, Ziyu; Chen, Shi; Peng, Yun; Xiao, Gelei; Luo, Peng; Zhang, Jian; Liu, Zaoqu; Cheng, Quan*; Zhang, Hao*Frontiers in Immunology, 2022, 13: 1040289.被引 1
  • IL2RB Is a Prognostic Biomarker Associated with Immune Infiltrates in Pan-Cancer
    Li, Guangyao; Wang, Yandong*; Cheng, Ya*Journal of Oncology, 2022, 2022: 2043880.被引 3
查看全部 →

发表信息

论文状态
公开发表
期刊
Journal of Immunology Research
发表日期
2022-01-06
卷期
第 2022 卷
页码
5254911
DOI
10.1155/2022/5254911
语言
ENGLISH
期刊等级
3区
成果收录
SCIE

作者

  • C

    Cheng, Xin (第一作者)

    2

  • C

    Cao, Yucheng

    2 · guangzhou univ chinese med

查看全部 8 位作者收起作者
  • W

    Wang, Xiaowei

    2

  • C

    Cheng, Lin

    2

  • L

    Liu, Yaqiong

    2

  • L

    Lei, Jun

    2

  • P

    Peng, Weijun (通讯)

    2

  • S

    Shi, Dazun (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417